Society for Brain Mapping and Therapeutics (SBMT) will hold its 15th Annual World Congress at the Millennium Biltmore Hotel in DTLA from April 13-15, 2018 including 400 speakers and 11 keynote speakers.
LOS ANGELES, March 15, 2018 /PRNewswire-USNewswire/ – The Society for Brain Mapping and Therapeutics (SBMT) officially announced today they will hold their 15th Annual World Congress at the Millennium Biltmore Hotel in DTLA from April 13-15, 2018. The event will include more than 400 scientists, engineers, physicians and surgeons where they will discuss pioneering technologies, policies and science advances in the fields including: multimodality imaging, nanoneurosurgery, nanobioelectronics, neurophotonics, cellular therapeutics (stem cell and neuro-immunotherapey), supercomputing, robotics (brain computer interface), neural transplantation and repair (double hand transplants), neuroengineering, Artificial Intelligence (AI), augmented reality and virtual reality in clinical neuroscience as well as computational and predictive modeling.
“I thank the members of the science committee and our 12 subcommittee members for helping us organizing this fantastic World Congress in LA," said Dr. Vicky Yamamato, Cancer Scientist at USC Department of Head and Neck Surgery and SBMT Executive Director. “We welcome all nonprofits, industry leaders, governmental agencies and academic centers to join us at this remarkable scientific convention." 繼續閱讀 →
Crises abound in this world, but as children of an omnipotent, loving Father, we can rest in His steadfast faithfulness to bring us to the other side of every storm. In this message, Dr. Stanley teaches from Paul’s second letter to Timothy, explaining what it means to face struggles with love, power, and a sound mind.
“If God allows a storm in your life, His ultimate purpose is to bring you out of it stronger," he says. When the winds begin to howl and the rains pour down, how will you respond?
United BioPharma (UBP, 6471) announced today that the company receives the approval from Thailand FDA an IND (Investigational New Drug) application for a multi-nation, multi-center, Phase III clinical trial with UB-421 monotherapy as HAART (Highly Active Anti-retroviral Therapy ) substitution in HIV infected patients.
The phase III trial is a randomized, open-label, controlled trial to investigate the efficacy and safety of UB-421 monotherapy as substitution for stable antiretroviral therapy in HIV-infected adults. Subjects will receive UB-421 by intravenous infusion at 25 mg/Kg, bi-weekly for a treatment period of 26 weeks. The subjects will be grouped into two cohorts, one cohort will continue the original HAART treatment as control and the other cohort will switch to receive UB-421 monotherapy for 26 weeks. After the treatment period, subjects in both cohorts will return to HAART and followed for another 22 weeks. The primary objective of this phase III trial is to evaluate the ability of UB-421 monotherapy in maintaining viral suppression in HIV patients who are stable on HAART.